Sort
82,697 grants matching “vaccine development”
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines
$747,395David R. Milich · Vaccine Research Institute Of San Diego · R01 · FY2008 · AI
Inhibiting poxvirus phosphatases: therapy and biodefense
$747,388Medical College Of Wisconsin · U01 · FY2004 · AI
IgM in the regulation of TB immunity
$747,370John R. Chan · Rbhs-New Jersey Medical School · R01 · FY2022 · AI
Glycosylation Mutants of Leishmania
$747,346Stephen M Beverley · Washington University · R01 · FY2009 · AI
North-Central California-Center For AIDS Research
$747,339University Of California Davis · P30 · FY2001 · AI
Molecular Regulation of B-Cell Differentiation and Function
$747,289Herbert Morse · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Characterizing Host-Virus Interactions in a New HIV Model Organism
$747,282Sara Sawyer · University Of Colorado · R01 · FY2023 · OD
Mechanisms and Population Genomics of Pneumococcal Antigenic Diversity
$747,273Marc Lipsitch · Harvard School Of Public Health · R01 · FY2012 · AI
The role of Trained Immunity and Mitochondrial dysfunction on INnate immunity in children and adolescents aGing with PHIV (TIMING-PHIV)
$747,219Nicholas T. Funderburg · Ohio State University · U01 · FY2025 · AI
San Antonio STI TM CRC
$747,200Joel Barry Baseman · University Of Texas Hlth Science Center · U19 · FY2008 · AI
Dynamics of antigen specific B and Tfh responses during acute and chronic HCV
$747,129Arash Grakoui · Emory University · R01 · FY2020 · AI
Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis B
$747,013Marc Ghany · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2011 · DK
FcRn-targeted mucosal HIV vaccine
$746,981Maria S. Salvato · University Of Maryland Baltimore · R01 · FY2015 · AI
FcRn-targeted mucosal HIV vaccine
$746,981Charles David Pauza · University Of Maryland Baltimore · R01 · FY2014 · AI
The Role of Nasal Mucosal Immunity and Microbiome on the Frequent Exacerbation Phenotype of COPD
$746,929Michael Bradley Drummond · Univ Of North Carolina Chapel Hill · R01 · FY2022 · HL
Universal VLP-Based Flu Vaccine:Broadly protective (universal) virus-like particle (VLP) based influenza vaccine that can neutralize a broad spectrum of influenza A virus subtypes.
$746,924Jose M Galarza · Technovax, Inc. · R44 · FY2018 · AI
Evolution and Transmission of Influenza Virus in Natural Human Infection
$746,786Adam Lauring · University Of Michigan At Ann Arbor · R01 · FY2022 · AI
Evolution and Transmission of Influenza Virus in Natural Human Infection
$746,786Adam Lauring · University Of Michigan At Ann Arbor · R01 · FY2021 · AI
Evolution and Transmission of Influenza Virus in Natural Human Infection
$746,786Adam Lauring · University Of Michigan At Ann Arbor · R01 · FY2020 · AI
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
$746,768Lisa B Hightow-Weidman · Univ Of North Carolina Chapel Hill · R01 · FY2021 · MD
UAB/BVAMC Clinical Center in COPD
$746,740Mark T Dransfield · University Of Alabama At Birmingham · U10 · FY2007 · HL
Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development
$746,698Thomas Denny · Duke University · N01 · FY2020 · AI
Cancer Center Support (Core) Grant
$746,692Tyler E Jacks · Massachusetts Institute Of Technology · P30 · FY2016 · CA
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo
$746,690Ge Liu · Vaxinnate Corporation · R01 · FY2013 · AI
Immunogenicity and Efficacy of a Bivalent Clade B gp120 Protein Boost for aDNA/MVA Vaccine
$746,628Hanne Andersen · Bioqual, Inc. · N01 · FY2017 · AI